Anti-Cancer

AXITINIB (BDAXIT) Tablet

$45.00

Axitinib provides patients with renewed hope and improved quality of life. However, its use necessitates careful oversight by oncology specialists, with diligent monitoring for adverse effects and therapeutic response. With continued research and clinical experience, Axitinib remains poised to make a lasting impact in the fight against kidney cancer.

Strength	Choose an option1mg5mg
	Clear

Quantity

AXITINIB (BDAXIT) Tablet quantity

Add to cart

Sku:

N/A

Tag:

AXITINIB BDAXIT

Description

Axitinib (BDAXIT) Tablet 1/5mg is an oral medication utilized in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It contains axitinib as its active ingredient, a potent and selective inhibitor of vascular endothelial growth factor receptor (VEGFR), which plays a crucial role in tumor angiogenesis and progression. By inhibiting VEGFR, axitinib blocks the formation of new blood vessels in tumors, thereby depriving them of nutrients and oxygen, and inhibiting their growth.

Key Features:

• VEGFR Inhibitor: Axitinib acts as a potent and selective inhibitor of vascular endothelial growth factor receptor (VEGFR), specifically VEGFR-1, VEGFR-2, and VEGFR-3. By blocking VEGFR signaling pathways, axitinib disrupts tumor angiogenesis, inhibits tumor growth, and reduces tumor vascularization.
• Treatment of Advanced RCC: Axitinib (BDAXIT) Tablet 1/5mg is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. It offers a targeted treatment option for patients with RCC who have progressed on previous therapies.
• Oral Administration: Axitinib (BDAXIT) Tablet 1/5mg is administered orally, typically twice daily, with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Dose Variability: Axitinib (BDAXIT) Tablet 1/5mg is available in two strengths, 1mg and 5mg, allowing for individualized dosing based on patient response and tolerability. This flexibility enables healthcare providers to tailor treatment to meet the specific needs of each patient.
• Efficacy: Clinical trials have demonstrated the efficacy of axitinib in prolonging progression-free survival and overall survival in patients with advanced RCC. It has shown superiority over placebo and other conventional treatments, offering new hope for patients with this aggressive cancer.
• Safety Profile: Axitinib generally has a manageable safety profile when used as directed. However, like all medications, it may be associated with certain side effects, including hypertension, diarrhea, fatigue, and hand-foot syndrome. Patients should be closely monitored for adverse reactions during treatment.
• Patient Education: Patients prescribed Axitinib (BDAXIT) Tablet 1/5mg should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
• Consultation with Healthcare Provider: Treatment with Axitinib (BDAXIT) Tablet 1/5mg should be initiated and monitored by a qualified oncologist or healthcare provider experienced in the management of renal cell carcinoma. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Axitinib (BDAXIT) Tablet 1/5mg for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to innovative targeted therapies is crucial to improving patient outcomes and quality of life for those with advanced RCC

Additional information